RP-UPLC法定量流感A H1N1与H3N2高产重配疫苗候选种子病毒的HA1蛋白
本文介绍了一种反相超高效液相色谱(RP-UPLC)方法,用于定量接种鸡胚后收获的流感A H1N1和H3N2亚型高产重配疫苗种子病毒中的HA1蛋白抗原。该方法可区分高产与低产重配株,从而在多个候选种子病毒中选出鸡胚内生长最好的疫苗候选株,为流感疫苗工业生产提供优势。
要点
- RP-UPLC可定量H1N1和H3N2重配种子病毒的HA1蛋白。
- 该方法能区分高产与低产重配株,辅助筛选最佳种子病毒。
- 监管机构目前唯一批准的HA抗原定量方法是SRID,但其耗时。
核心结论
- RP-UPLC法可定量流感A H1N1和H3N2高产重配疫苗种子病毒的HA1蛋白,并区分高产与低产重配株。
研究设计与样本
- 方法学开发:采用反相超高效液相色谱(RP-UPLC)定量接种鸡胚后收获的流感A H1N1和H3N2高产重配疫苗种子病毒中的HA1蛋白抗原。
主要发现
- RP-UPLC法能够区分高产与低产重配株,以选择鸡胚内生长最好的疫苗候选种子病毒。
关键数值与推荐
- 监管机构目前唯一批准的疫苗HA抗原定量方法是单径向免疫扩散试验(SRID),该法依赖抗体且耗时。
- RP-UPLC为不依赖抗体的时间高效方法,同类方法还包括RP-HPLC和SE-HPLC。
临床怎么用
- 在工业规模流感疫苗生产中,可用RP-UPLC直接监测候选重配种子病毒的HA1浓度,从多个病毒种子候选中选择产量最好的HA流感重配株。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The only effective measure to decrease morbidity and mortality caused by the influenza virus in the human population is worldwide vaccination. Vaccination produces neutralizing antibodies that target the HA1 subunit of the HA (hemagglutinin) protein and are strain specific. The effectiveness of new influenza vaccines are linked to two factors, the correct prediction of the circulating strains in the population in a particular season and the concentration of the HA1 protein in the vaccine formulation. With the advent of the licensing of quadrivalent vaccines, pharmaceutical manufacturers are under considerable pressure due to time constraints and dedicated resources to deliver 194-198 million doses (2020-2021 U.S. market) of vaccine. Considering the valuable resources needed to produce the influenza vaccine in a timely manner, the efficient quantitation of the HA1 protein (the main component in the influenza vaccine) is required. Currently the only method approved by regulatory agencies for quantitation of the HA antigen in vaccines is the single radial immunodiffusion assay (SRID), an antibody dependent assay that is not time efficient. Time efficient methods that are antibody independent e.g. reverse phase-high performance liquid chromatography (RP-HPLC) or size exclusion-HPLC (SE-HPLC) are available. An improved method implementing reverse phase-ultra performance liquid chromatography (RP-UPLC) has been developed to quantitate the HA1 protein antigen present in the high yield reassortant vaccine seed viruses from influenza A H1N1 and H3N2 subtypes harvested from inoculated embryonated chicken eggs. This method differentiates between high yield and lower yielding reassortants in order to select the best vaccine candidate seed virus with the highest growth 'in ovo'. This direct capability to monitor the HA1 concentration of potential reassortant seed viruses and to choose the best yielding HA influenza reassortant when faced with multiple viral seed candidates provides a major advantage on the industrial scale to the influenza vaccine process.
引用
- Fulvini AA, Tuteja A, Le J, et al. HA1 (Hemagglutinin) quantitation for influenza A H1N1 and H3N2 high yield reassortant vaccine candidate seed viruses by RP-UPLC. Vaccine. 2020. PMID: 33341306. doi:10.1016/j.vaccine.2020.12.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。